Prima BioMed (NASDAQ:IMMP) Share Price Passes Below Fifty Day Moving Average – Should You Sell?

Prima BioMed Ltd (NASDAQ:IMMP) shares passed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $1.04 and traded as low as $0.4379. Prima BioMed shares last traded at $0.4424, with a volume of 743,667 shares traded.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IMMP. Wall Street Zen upgraded shares of Prima BioMed to a “hold” rating in a report on Saturday, April 18th. Citizens Jmp downgraded shares of Prima BioMed from an “outperform” rating to a “market perform” rating in a report on Friday, March 13th. Robert W. Baird downgraded shares of Prima BioMed from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $7.00 to $1.00 in a report on Friday, March 13th. Finally, Maxim Group downgraded shares of Prima BioMed from a “buy” rating to a “hold” rating in a report on Friday, March 13th. Three analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $5.50.

Prima BioMed Trading Down 3.7%

The firm’s 50-day moving average price is $1.04 and its two-hundred day moving average price is $1.95.

Prima BioMed (NASDAQ:IMMP) last issued its earnings results on Friday, January 30th. The biotechnology company reported ($0.10) earnings per share for the quarter. The firm had revenue of $1.37 million for the quarter.

Institutional Trading of Prima BioMed

A hedge fund recently raised its stake in Prima BioMed stock. Jane Street Group LLC increased its holdings in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 51,574 shares of the biotechnology company’s stock after acquiring an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.32% of the company’s stock.

About Prima BioMed

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.